Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31144604 | 0.82 | DYRK1A (0.38) | HCAR1MKNK2DYRK1A | |
| SCHEMBL14852261 | 0.74 | CHRNB2 (0.52) | — | |
| SCHEMBL31144777 | 0.73 | ATM (0.58) | HCAR1 | |
| SCHEMBL31144666 | 0.70 | ATM (0.59) | DRD2DRD3HTR6 | |
| SCHEMBL31144610 | 0.69 | NR1H2 (0.52) | HCAR1IGF1R | |
| SCHEMBL31144585 | 0.69 | RAB9A (0.44) | DYRK1A | |
| SCHEMBL2191972 | 0.69 | HCAR1 (0.55) | HCAR1DYRK1A | |
| SCHEMBL14852170 | 0.69 | GAA (0.44) | ADRA2C | |
| SCHEMBL31144772 | 0.68 | ATM (0.58) | — | |
| SCHEMBL31144636 | 0.68 | ATM (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015328-A1 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2026-01-15 | — | — | US | disclosed |
| WO-2024194460-A2 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2024-09-26 | — | — | WO | disclosed |
| EP-4434972-A1 | ATM KINASE INHIBITORS | Eberhard-Karls-Universität Tübingen (DE) | 2024-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015328-A1 | ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | PNMT 3885/4885HCAR1 3683/4885ADRA2A 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.